Immunoconjugates are being explored as novel cancer therapies with the promise of target-specific drug delivery. The immunoconjugate, huN901-DM1, composed of the humanized monoclonal IgG 1 antibody, huN901, and the maytansinoid drug, DM1, is being tested in clinical trials to treat small cell lung carcinoma (SCLC). huN901-DM1 contains an average of three to four DM1 drug molecules per huN901 antibody molecule. The drug molecules are linked to huN901 through random modification of huN901 at e-amino groups of lysine residues, thus yielding a heterogeneous population of conjugate species. We studied the drug distribution profile of huN901-DM1 by electrospray time-of-flight mass spectrometry (ESI-TOFMS), which showed that one to six DM1 drug molecules were attached to an antibody molecule. Both light and heavy chains contained linked drugs. The conjugation sites in both chains were determined by peptide mapping using trypsin and Asp-N protease digestion. Trypsin digestion identified modified lysine residues, since these residues were no longer susceptible to enzymatic cleavage after conjugation with the drug. With respect to Asp-N digestion, modified peptides were identified by observing a mass increase corresponding to the modification. The two digestion methods provided consistent results, leading to the identification of 20 modified lysine residues in both light and heavy chains. Each lysine residue was only partially modified. No conjugation sites were found in complementarity determining regions (CDRs). Using structural models of human IgG 1 , it was found that modified lysine residues were on the surface in areas of structural flexibility and had large solvent accessibility.

Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.

Great successes have been achieved in developing perovskite light-emitting devices (LEDs) with blue, green, red, and near-infrared emissions. However, as key optoelectronic devices, yellow-colored perovskite LEDs remain challenging, mainly due to the inevitable halide separation in mixed halide perovskites under high bias, causing undesired color change of devices. In addition to this color-missing problem, the intrinsic toxicity and poor stability of conventional lead-halide perovskites also restrict their practical applications. We herein report the fabrication of stable yellow LEDs based on a ternary copper halide CsCu2I3, addressing the color instability and toxicity issues facing current perovskite yellow LED’s compromise. Joint experiment–theory characterizations indicate that the yellow electroluminescence originates from the broadband emission of self-trapped excitons centered at 550 nm as well as the comparable and reasonably low carrier effective masses favorable for charge transport. With a maximum luminance of 47.5 cd/m2 and an external quantum efficiency of 0.17%, the fabricated yellow LEDs exhibit a long half-lifetime of 5.2 h at 25 °C and still function properly at 60 °C with a half-lifetime of 2.2 h, which benefits from the superior resistance of CsCu2I3 to heat, moisture, and oxidation in ambient environmental conditions. The results obtained promise the copper halides with broadband light emission as an environment-friendly and stable yellow emitter for the LEDs compatible with practical applications.

Currently, the blue perovskite light-emitting diodes (PeLEDs) suffer from a compromise in lead toxicity and poor operation stability, and most previous studies have struggled to meet the crucial blue NTSC standard. In this study, electrically driven deep-blue LEDs (∼445 nm) based on zero-dimensional (0D) Cs3Cu2I5 nanocrystals (NCs) were demonstrated with the color coordinates of (0.16, 0.07) and a high external quantum efficiency of ∼1.12%, comparable with the best-performing blue LEDs based on lead-halide perovskites. Encouraged by the remarkable stability of Cs3Cu2I5 NCs against heat and environmental oxygen/moisture, the proposed device was operated in a continuous current mode for 170 h, producing a record half-lifetime of ∼108 h. The device stability was further verified by an aggressive thermal cycling test (300–360–300 K) and a 35-day storage test. Together with the eco-friendly features and facile colloidal synthesis technique, the 0D Cs3Cu2I5 NCs can be therefore regarded as a promising candidate for deep-blue LEDs applications.

Obesity increases the risk for a number of diseases including cardiovascular diseases and type 2 diabetes. Excess saturated fatty acids (SFAs) in obesity play a significant role in cardiovascular diseases by activating innate immunity responses. However, the mechanisms by which SFAs activate the innate immune system are not fully known. Here we report that palmitic acid (PA), the most abundant circulating SFA, induces myocardial inflammatory injury through the Toll-like receptor 4 (TLR4) accessory protein MD2 in mouse and cell culture experimental models. Md2 knockout mice are protected against PA- and high-fat diet-induced myocardial injury. Studies of cell surface binding, cell-free protein–protein interactions and molecular docking simulations indicate that PA directly binds to MD2, supporting a mechanism by which PA activates TLR4 and downstream inflammatory responses. We conclude that PA is a crucial contributor to obesity-associated myocardial injury, which is likely regulated via its direct binding to MD2.